Pilot Study: Evaluating the Feasibility of Accelerated rTMS Treatment Delivered at Individual Resonant Frequencies for In-patient Subjects Suffering From Major Depressive Disorder

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The investigators are studying the feasibility, safety, and tolerability of administering accelerated repetitive Transcranial magnetic stimulation(a-rTMS) at frequencies other than standard 10 Hz for in-patient Subjects diagnosed with Major Depressive Disorder. Participants will be recruited from the Resnick Neuropsychiatric Hospital. This study will enroll 30 participants who will undergo up to three brain activity recordings, one MRI scan, one TMS procedure to determine the appropriate frequency and intensity for treatment, daily symptom assessments, and 25 TMS treatments. Participants will be asked to participate for up to 2 weeks.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

• All subjects must be between 18-65 years of age.

• Must have confirmed diagnosis of moderate to severe Major Depressive Disorder (single or recurrent episode) as defined by a HAM-D score of 17 or higher.

• Failure to respond to a minimum of 2 trials of antidepressant medication

• Failure to respond from at least two different agent classes

• Accompanied by at least two evidence-based augmentation therapies (Benzodiazepines do not count).

• Must have a trial of psychotherapy known to be effective in the treatment of MDD of an adequate frequency and duration.

• Subjects are willing and able to adhere to the accelerated treatment schedule.

Locations
United States
California
UCLA TMS Service and Research Service
RECRUITING
Los Angeles
Contact Information
Primary
Nikita Vincecruz, BS
nvincecruz@mednet.ucla.edu
310-825-4781
Time Frame
Start Date: 2025-04-01
Estimated Completion Date: 2027-02-22
Participants
Target number of participants: 30
Treatments
Experimental: Open-label TMS
Related Therapeutic Areas
Sponsors
Leads: University of California, Los Angeles

This content was sourced from clinicaltrials.gov

Similar Clinical Trials